References
- Bawero F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997; 39( Suppl A): 1-6.
- Diekema DJ, Pfaller MA, Jones RN, et al. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. Int J Antimicrob Agents 2000; 13: 257–271.
- McGowan JE. Control of antimicrobial resistance prob-lems in the critical care unit. Antibiot Clinicians 2000; 4(Suppl 1): 38–45.
- Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998; 41( Suppl D): 7-11.
- Bonomo RA. Multiple antibiotic-resistant bacteria in long-term-care facilities: an emerging problem in the practice of infectious diseases. Clin Infect Dis 2000; 31: 1414–1422.
- Colley EW, McNicol MW, Bracket PM. Methicillin-resis-tant staphylococci in a general hospital. Lancet 1965; 191: 595–597.
- Fridkin SK. Vancomycin-intermediate and resistant Staphylococcus aureus: What the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: 108–115.
- Fridkin SK, Gaynes, RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999; 20: 303–316.
- Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U. S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992; 13: 582–586.
- Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316: 927–931.
- Sieradzki K, Villari P, Tomasz A. Decreased susceptibil-ities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998; 42: 100–107.
- Von Eiff C, Reinert RR, Kresken M, Brauers J, Hafner D, Peters G. Nationwide German multicenter study on preva-lence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin/dal-fopristin. J Clin Microbiol 2000; 38: 2819–2823.
- Cooper GL, Given DB. Vancomycin: a comprehensive review of 30 years of clinical experience. Lilly Research Laboratories, 1986.
- Moellering RC. Vancomycin-resistant enterococci. Clin Infect Dis 1998; 26: 1196–1199.
- Woodford N, Johnson AP, Morrison D, Speller DC. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995; 8: 585–615.
- Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacoki-netic properties and therapeutic potential. Drugs 1990; 40: 449–486.
- Diekema DJ, Jones RN. Oxazolidinones. A review. Drugs 2000; 59: 7–16.
- Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin/dalfopristin (RP 59500, Synercid”) tested against over 28,000 recent clini-cal isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998; 31: 437–451.
- Jones RN, Hare RS, Sabatelli FJ, the Ziracin Susceptibility Testing Group. In vitro Gram-positive antimicro-bial activity of evernimicin (SCH 27899), a novel oligosaccha-ride, compared with other antimicrobials: A multicentre inter-national trial. J Antimicrob Chemother 2001; 47: 15–25.
- Candiani G, Abbondi M, Borgonovi M, Romand G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44: 179–192.
- Goldstein BP, Candiani GP, Arain TM, et al. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1995; 39: 1580-1588.
- Kenny MT, Brackman MA, Dulworth JK. In vitro activ-ity of the semisynthetic glycopeptide amide MDL 63,246. Antimicrob Agents Chemother 1995; 39: 1589-1590.
- Malabarba A, Ciabatti R, Romano G, et al. BI 397: a new developmental semisynthetic glycopeptide antibiotic. 38th Interscience Conference on Antimicrobial Agents and Chemother (ICAAC). Abst. 259, 1998.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: 7th edition: Approved standard M2-A7. Wayne, PA: NCCLS, 2000.
- National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial susceptibility testing. Document M100-S11. Wayne, PA: NCCLS, 2001.